Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Preoperative hormone therapy trials for breast cancer
Autore:
Cheung, KL; Robertson, JFR;
Indirizzi:
City Hosp, Professorial Surg Unit, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB g Unit, Nottingham NG5 1PB, England
Titolo Testata:
BREAST
fascicolo: 1, volume: 10, anno: 2001,
pagine: 1 - 5
SICI:
0960-9776(200102)10:1<1:PHTTFB>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-STIMULATING FACTOR; PRIMARY TAMOXIFEN THERAPY; PRIMARY TUMOR REMOVAL; ELDERLY PATIENTS; RANDOMIZED TRIAL; WOMEN; RECEPTOR; CHEMOTHERAPY; ESTROGEN; DISEASE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Robertson, JFR City Hosp, Professorial Surg Unit, Hucknall Rd, Nottingham NG5 1PB, England City Hosp Hucknall Rd Nottingham England NG5 1PB , England
Citazione:
K.L. Cheung e J.F.R. Robertson, "Preoperative hormone therapy trials for breast cancer", BREAST, 10(1), 2001, pp. 1-5

Abstract

Preoperative hormone therapy for breast cancer has the potential to downstage a primary tumour hence increasing operability as well as making breast conservation feasible. Whether it will achieve any clinically significant survival benefit remains to be elucidated. Preoperative hormone therapy, in contrast to neoadjuvant chemotherapy, produces less severe side effects andcan be continued throughout the perioperative period. Presurgical studies have demonstrated anti-tumour effects of hormone therapy, e.g. down-regulation of ER. Current clinical trials have shown that, in patients with ER positive tumours, a response approaching 70% is reached in approximately threemonths using the traditional hormonal agent tamoxifen. The tumour seldom progresses during this period. New agents (such as third generation aromatase inhibitors and pure anti-oestrogens) may produce more profound and rapid responses. Future trials are required to identify factors other than ER to precisely predict response so that appropriate patients can be selected. The best agents, the ideal methods of monitoring response and the optimum duration of therapy also need to be identified. Clinical trials also need to test if pre- and perioperative hormone therapy is superior to conventional adjuvant hormone therapy in patients with early breast cancer. (C) 2001 Harcourt Publishers Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/07/20 alle ore 05:17:45